# To Evaluate Pharmacokinetics and Pharmacodynamics of Z-215 in Healthy Male Subjects

> **NCT02509923** · PHASE1 · COMPLETED · sponsor: **Zeria Pharmaceutical** · enrollment: 54 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Z-215 10mg
- **DRUG:** Z-215 20mg
- **DRUG:** Rabeprazole Sodium 10mg
- **DRUG:** Rabeprazole Sodium 20mg

## Key facts

- **NCT ID:** NCT02509923
- **Lead sponsor:** Zeria Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2016-03
- **Final completion:** 2016-09
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2016-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02509923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02509923, "To Evaluate Pharmacokinetics and Pharmacodynamics of Z-215 in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02509923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*